Ozempic vs Wegovy: Same Drug, Different Prices — Here's Why

One fact governs everything else here. Ozempic and Wegovy are the same drug. The active ingredient is semaglutide. The molecule is identical. They are made by the same manufacturer (Novo Nordisk) in the same facilities. So why are they two products with two names, two prices, two FDA approvals, and two different insurance coverage rules?

The answer is regulatory and commercial — and once you understand it, you can spot the pricing arbitrage that millions of patients miss. This guide explains the difference between the two brands, why one is often dramatically cheaper than the other depending on your situation, and how to think about the choice in 2026.

Already settled on compounded semaglutide and only after a seller? Our best semaglutide providers list is the page you want. Otherwise, read on.

Key Takeaways

• Same active ingredient (semaglutide), same manufacturer (Novo Nordisk).
• Different FDA approvals: Ozempic is approved for type 2 diabetes; Wegovy is approved for chronic weight management.
• Different doses: Ozempic tops out at 2.0 mg weekly; Wegovy goes up to 2.4 mg.
• Different list prices: Ozempic is ~$969/month, Wegovy is ~$1,349/month.
• Insurance treats them very differently — Ozempic is covered for diabetes; Wegovy coverage for obesity is far more limited.
• Compounded semaglutide bypasses both and is widely available at $129–$249/month.

The Same Molecule, Two Products

Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a hormone your gut releases after meals. It binds to GLP-1 receptors in the brain to suppress appetite, slows gastric emptying so you feel full longer, and improves insulin sensitivity. The science is identical regardless of which brand you take.

Why are there two brands? Because Novo Nordisk pursued two separate FDA approvals for semaglutide — one for diabetes (Ozempic, approved 2017) and one for obesity (Wegovy, approved 2021). Each approval requires its own clinical trial program, its own labeling, its own pricing strategy, and — critically — its own insurance reimbursement codes.

This is a common pharmaceutical strategy. The active ingredient is the same; the regulatory packaging and the marketing are different. (For the parallel case in tirzepatide, see Mounjaro vs Zepbound.)

What's Actually Different

1. Dosing

This is the only meaningful clinical difference. Ozempic and Wegovy use the same titration schedule for the first 16 weeks, then diverge:

Wegovy's higher maintenance dose (2.4 mg) was the dose tested in the STEP-1 obesity trial that produced 14.9% weight loss. Ozempic was originally tested at lower diabetes-focused doses, though Novo Nordisk later added a 2.0 mg option for diabetes patients who needed more glycemic control.

In practice: Wegovy gives you ~20% more semaglutide per dose at the maintenance level. For weight loss, that matters. For diabetes control, the difference is small.

2. FDA Indication

• Ozempic carries two approvals, both confined to type 2 diabetes in adults: glycemic control, and — where heart disease is already known — cutting the risk of major adverse cardiovascular events.
• Wegovy also carries two. The first is long-term weight management, open to adults at BMI ≥30, or at BMI ≥27 where a weight-related comorbidity comes with it. The second arrived in 2024 on the strength of the SELECT trial. It applies where an adult carries obesity or overweight AND established cardiovascular disease, and what it claims is a reduction in major adverse cardiovascular events.

This is why your prescribing doctor matters. Nothing stops a doctor writing Ozempic off-label for weight loss. What stops it is the claim: absent a documented diabetes diagnosis, most insurers refuse.

3. Pricing

List prices (no insurance, no coupon) as of early 2026:

• Ozempic: ~$969/month
• Wegovy: ~$1,349/month

The Wegovy premium reflects the higher maintenance dose plus Novo Nordisk's pricing strategy for the obesity market, which has different payer dynamics than diabetes. In real life, almost no one pays the full list price — the actual cost depends entirely on your insurance and which manufacturer savings programs you qualify for.

4. Insurance Coverage

This is where the real divergence happens. As of 2026:

• Ozempic is covered by virtually every major insurer for type 2 diabetes patients, often at a $25–$50 monthly co-pay after deductible.
• Wegovy is covered by *some* commercial insurers for obesity, but coverage is patchy. Roughly 25–35% of commercial plans cover it, often with strict prior authorization (BMI requirements, prior weight-loss program documentation, etc.). Medicare does not cover Wegovy for obesity (a limited exception exists for cardiovascular indication after 2024).

This insurance gap is why the off-label Ozempic-for-weight-loss market exploded in 2022–2024. Patients without a diabetes diagnosis frequently asked their doctors to write off-label Ozempic prescriptions because insurance was more likely to cover it. The FDA and several state medical boards have since cracked down on this practice.

For a complete look at the insurance landscape, see our Cost & Insurance pillar guide.

The Pricing Arbitrage (and Why It Mostly Disappeared)

From 2021 to 2024, there was a clear arbitrage: get an off-label Ozempic prescription, pay your diabetes copay, and use the lower-dose Ozempic for weight loss. This worked because:

1. Insurance covered Ozempic but not Wegovy.
2. Both drugs are semaglutide.
3. A 1.0 mg or 2.0 mg Ozempic dose still produced meaningful weight loss.

This loophole is largely closed in 2026 for three reasons:

1. Insurance audits caught up. PBMs now require diabetes documentation (HbA1c lab results) for Ozempic claims.
2. Novo Nordisk supply allocation prioritized Wegovy as the obesity-indicated brand, making off-label Ozempic harder to get filled.
3. Compounded semaglutide became dramatically cheaper than either brand, with no insurance friction.

The modern arbitrage isn't Ozempic-vs-Wegovy. It's brand-vs-compounded.

Compounded Semaglutide: The Real Cheat Code

Compounded semaglutide is produced by licensed compounding pharmacies (503A and 503B) and dispensed through telehealth providers. Identical active ingredient, and nothing like the same price:

Before choosing compounded, understand the safety considerations. We cover them in detail in our guide on compounded semaglutide safety. Short version: stick to providers who use 503A pharmacies registered with state boards, or 503B outsourcing facilities registered with the FDA. Verify with LegitScript before signing up.

Our best GLP-1 providers ranking only includes providers that meet these standards. Top picks for compounded semaglutide in 2026:

• CoreAge Rx — $149/month, 503B-sourced, ships to all 50 states
• Hims — $199/month, broad availability, frequent promo codes
• Henry Meds — $297/month, established player with strong support

Use our GLP-1 savings calculator to compare your specific situation against all three.

Side Effects: Identical

Because it's the same molecule, the side effect profile is identical between Ozempic, Wegovy, and compounded semaglutide. In the 1–4 weeks following any dose increase, expect nausea, constipation, headache, fatigue, and vomiting now and then. Serious adverse events (pancreatitis, gallbladder disease, kidney injury) are rare but real.

For a complete management guide, read our deep dive on managing semaglutide side effects.

Bottom Line

Ozempic and Wegovy are the same drug at different doses with different FDA labels and very different insurance treatment. Type 2 diabetes makes the decision easy: Ozempic, on all three counts — coverage, an appropriate dose, and a cost you can live with. If you don't have diabetes and are using GLP-1 for weight management, Wegovy is the FDA-on-label option but is rarely affordable without insurance.

For most weight-loss patients in 2026, the practical answer is *neither brand*. Compounded semaglutide through a reputable telehealth provider costs 80–90% less and uses the same molecule. The main reason to choose brand-name Wegovy is if your insurance covers it at a low co-pay or you specifically need the FDA-approved formulation for medical-legal reasons (some employers, some specific patient profiles).

For more on the broader semaglutide picture, see our full semaglutide drug guide. For the tirzepatide alternative, see Semaglutide vs Tirzepatide.